Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Beigene Ltd ADR (NQ: BGNE )

204.21 +1.57 (+0.77%)
Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Beigene Ltd ADR

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
16 17 Next >
U.S.-China Audit Deal Won't Slow Hong Kong Dual Listing Train, Analysts Say
Key Takeaways: Despite a landmark U.S.-China information-sharing agreement, some predict dual listings in New York and Hong Kong will remain the preferred choice for Chinese... 
Via Benzinga
7 Chinese Stocks to Sell While You Still Can
These Chinese stocks have had a rough outing at the stock markets of late, as their underlying businesses buckle under the economic pressure 
Via InvestorPlace
Why Bed Bath & Beyond Jumped Around 25%; Here Are 68 Biggest Movers From Yesterday
Gainers 
Via Benzinga
Recap: BeiGene Q2 Earnings
  BeiGene (NASDAQ:BGNE) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings BeiGene reported an EPS of $-5.56. 
Via Benzinga
Catalent, Tellurian And Other Big Losers From Monday
U.S. stocks closed lower with the Dow Jones dropping around 185 points on Monday. Here is the list of some big stocks moving lower in the previous session. 
Via Benzinga
Why Splunk Is Trading Lower By Around 10%; Here Are 28 Stocks Moving Premarket
Gainers ECMOHO Limited (NASDAQ: MOHO) shares rose 47% to $0.2149 in pre-market trading. 
Via Benzinga
Tesla, Autodesk And Some Other Big Stocks Moving Higher In Today's Pre-Market Session
Snowflake Inc. (NYSE: SNOW) surged 17.4% to $187.18 in pre-market trading after the company reported better-than-expected Q2 sales results and issued product revenue guidance. 
Via Benzinga
Recap Of Tuesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
BeiGene Announces Acceptance of 11th Regulatory Submission for PD-1 Inhibitor Tislelizumab in China
From BeiGene
Via Business Wire
7 Monkeypox Vaccine Stocks to Buy Before They Shoot Higher
These monkeypox stocks could be among the best choices to buy in August. Each can make great investments as government responses ramp up. 
Via InvestorPlace
BeiGene Announces Strategic Alliance with Ontada to Improve U.S. Community Oncology Care
From BeiGene
Via Business Wire
Recap of Tuesday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
BeiGene Announces Positive Global Phase 3 Trial Results for PD-1 Inhibitor Tislelizumab in First-Line Unresectable Hepatocellular Cancer
From BeiGene
Via Business Wire
Coinbase, MercadoLibre And Some Other Big Stocks Recording Gains On Thursday
U.S. stocks closed mixed on Thursday following the release of weekly jobless claims data. Here is the list of some big stocks moving higher in the previous session. 
Via Benzinga
BeiGene Reports Second Quarter 2022 Financial Results
From BeiGene, Ltd.
Via Business Wire
Biotech Investors: August's Key PDUFA Catalysts You Must Know
Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the... 
Via Benzinga
Beigene's Inspections Delay Suggest Eventual Approval, Says This Analyst
Beigene Limited (NASDAQ: BGNE) provided a regulatory update on the anticipated US approval decision for the Biological License Application for tislelizumab in 2L metastatic esophageal squamous cell... 
Via Benzinga
U.S. FDA Defers Decision On BeiGene's Filing For Esophageal Carcinoma Due To Pending Inspection
The U.S. Food and Drug Administration (FDA) has deferred decision on the Biologics License Application (BLA) for BeiGene’s (NASDAQ: BGNE) tislelizumab as a second-line treatment for patients with... 
Via Benzinga
The Daily Biotech Pulse: Much Awaited FDA Nod For Novavax's COVID-19 Shot, DSMB Suggests ContraFect To Stop Antimicrobial-Resistant Infection Study, CytomX Restructures
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
BeiGene Provides Regulatory Update on the U.S. Biologics License Application (BLA) for PD-1 Inhibitor Tislelizumab in 2L ESCC
From BeiGene
Via Business Wire
BeiGene Appoints Chan Lee as General Counsel
From BeiGene
Via Business Wire
Week In Review: Sequoia China Raises $9 Billion For Healthcare And Technology Investments
New investments in China life science may have declined over the last year, but large investment companies continue to raise large sums to invest. Sequoia China has raised about $9 billion to make... 
Via Talk Markets
BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies
From BeiGene
Via Business Wire
Week In Review: Henlius Signs $196 Million Deal For Two Oncology Bifunctional Sialidase Candidates
Shanghai Henlius Biotech acquired Greater China rights to two early-stage bifunctional sialidase candidates from Palleon Pharma, a Waltham, MA biopharma, in a deal with $196.5 million in development... 
Via Talk Markets
Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates
The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment. 
Via Benzinga
Novartis' Tislelizumab Extends Overall Survival In Late-Stage Esophageal Cancer Study
Novartis AG (NYSE: NVS) announced results from the Phase 3 RATIONALE 306 trial of tislelizumab plus chemotherapy in patients with unresectable, locally advanced recurrent or metastatic esophageal... 
Via Benzinga
BeiGene Announces Late-Breaking Data at ESMO GI Showing Overall Survival Benefit for Tislelizumab Plus Chemotherapy in First-Line Advanced or Metastatic Esophageal Squamous Cell Carcinoma
From BeiGene
Via Business Wire
7 Penny Stocks That Could Triple in 2022
Penny stocks are affordable and some with credible business models in all likelihood have the potential to generate superior returns. 
Via InvestorPlace
BeiGene Announces Acceptance of Supplemental Biologics License Application in China for Anti-PD-1 Inhibitor Tislelizumab
From BeiGene
Via Business Wire
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.